Affymax (NASDAQ: [[ticker:AFFY]]), the Palo Alto, CA-based developer of an anemia drug, said today it has raised $50 million in gross proceeds through a stock offering. The company sold about 8.47 million new shares at $5.90 apiece, about an 8.5 percent discount from yesterday’s closing stock price of $6.45. Lazard Capital Markets and Stifel Nicolaus Weisel managed the offering.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
